Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TI-0032-III in Relapsed and Refractory Autoimmune Diseases
NCT07413341Phase 1Recruiting
- Sponsor
- Therorna
- Start
- Jan 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TI-0032-III in systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis (SSc) and 2 more, sponsored by Therorna. Primary endpoint: Safety outcomes at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
TI-0032-III
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromesystemic sclerosis (SSc)inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07413341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413341.